Enteric coating, coated pink, round, biconvex.
1 tab. Trimetazidine dihydrochloride 35 mg.
Excipients: gipromelloza, microcrystalline cellulose, colloidal silicon dioxide (aerosil), magnesium stearate, Opadry II (gipromelloza, lactose monohydrate, Polydextrose, macrogol, titanium dioxide, iron oxide yellow, iron oxide red).
Clinico-pharmacological group: The drug that improves myocardial metabolism and neurosensory organs in conditions of ischemia.
Pharmacological action
The drug, which improves myocardial metabolism and neurosensory organs in ischemia. Has antianginalnoe, antihypoxia action. Directly affecting the cardiomyocytes and neurons of the brain, improves their metabolism and function. Cytoprotective effect explained by rising energy potential, activation of oxidative decarboxylation and the rationalization of consumption of oxygen (increased aerobic glycolysis and the blockade of fatty acid oxidation). Supports myocardial contractility, prevents reduction of intracellular ATP content and fosfokreatinina.
In acidosis, normalizes the function of membrane ion channels, prevents the accumulation of calcium and sodium in cardiomyocytes, normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and phosphate levels, due to myocardial ischemia and reperfusion.
It prevents the damaging action of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in the ischemic area, increases the duration of the electric potential, reduces the yield of CK from the cells and the severity of ischemic myocardial damage.
When angina reduces the frequency of attacks (which lowers the consumption of nitrates). After 2 weeks of treatment increased exercise tolerance, reduced blood pressure drops. Against the background of the drug in patients improves hearing and results of vestibular tests, decreased dizziness and tinnitus.
In vascular pathology eye on the background of the drug restored the functional activity of the retina.
Pharmacokinetics
Absorption after taking the drug inside trimetazidine quickly and almost completely absorbed from the gastrointestinal tract. Bioavailability - 90%. Time to reach Cmax in blood plasma - 5 hours after a single administration of trimetazidine 35 mg Cmax in blood plasma is about 115 ng / ml.
Distribution
Binding to plasma proteins - 16%. Easily penetrates through histohematogenous barriers.
Withdrawal
T1 / 2 was 6.5 hours excreted by the kidneys (about 60% - unchanged).
Statement
Coronary heart disease: prevention of angina attacks (in the complex therapy);
chorioretinal circulatory disorders;
Vertigo of vascular origin;
kohleo-vestibular disorders of ischemic nature (tinnitus, hearing loss).
Dosage regimen
Assign to 35 mg (1 tab.) 2 times / day. Tablets are taken orally, during a meal in the morning and evening. Duration of therapy is determined individually.
Side effect
On the part of the digestive system: rarely - stomachalgia, nausea, vomiting.
Allergic reactions: itching.
Other: rarely - headache, feeling of palpitations.
Contraindications
renal failure (CC <15 ml / min);
marked disturbances of liver function;
Pregnancy
Lactation (breastfeeding);
childhood and adolescence to 18 years (efficacy and safety of the drug not established);
Hypersensitivity to the drug's components.
Pregnancy and lactation
The drug is contraindicated during pregnancy and lactation (breastfeeding).
Application for violations of liver function
Contraindications disturbancies liver
Application for violations of renal function
Contraindicated in renal insufficiency (CC <15 ml / min).
Cautions
The product is not intended for relief of angina attacks. In the case of an attack of angina should be correction of treatment.
Effects on ability to drive vehicles and management mechanisms
The product has no effect on the ability to occupations potentially hazardous activities requiring attention and speed of psychomotor reactions.
Overdose
Currently, cases of overdosing Angiozil retard not reported.
Drug Interactions
Drug Interactions drug Angiozil retard not described.
Terms and Conditions of storage
List B. The drug should be stored out of reach of children, dry, dark place at temperatures not above 25 ° C. Shelf life - 2 years.
1 tab. Trimetazidine dihydrochloride 35 mg.
Excipients: gipromelloza, microcrystalline cellulose, colloidal silicon dioxide (aerosil), magnesium stearate, Opadry II (gipromelloza, lactose monohydrate, Polydextrose, macrogol, titanium dioxide, iron oxide yellow, iron oxide red).
Clinico-pharmacological group: The drug that improves myocardial metabolism and neurosensory organs in conditions of ischemia.
Pharmacological action
The drug, which improves myocardial metabolism and neurosensory organs in ischemia. Has antianginalnoe, antihypoxia action. Directly affecting the cardiomyocytes and neurons of the brain, improves their metabolism and function. Cytoprotective effect explained by rising energy potential, activation of oxidative decarboxylation and the rationalization of consumption of oxygen (increased aerobic glycolysis and the blockade of fatty acid oxidation). Supports myocardial contractility, prevents reduction of intracellular ATP content and fosfokreatinina.
In acidosis, normalizes the function of membrane ion channels, prevents the accumulation of calcium and sodium in cardiomyocytes, normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and phosphate levels, due to myocardial ischemia and reperfusion.
It prevents the damaging action of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in the ischemic area, increases the duration of the electric potential, reduces the yield of CK from the cells and the severity of ischemic myocardial damage.
When angina reduces the frequency of attacks (which lowers the consumption of nitrates). After 2 weeks of treatment increased exercise tolerance, reduced blood pressure drops. Against the background of the drug in patients improves hearing and results of vestibular tests, decreased dizziness and tinnitus.
In vascular pathology eye on the background of the drug restored the functional activity of the retina.
Pharmacokinetics
Absorption after taking the drug inside trimetazidine quickly and almost completely absorbed from the gastrointestinal tract. Bioavailability - 90%. Time to reach Cmax in blood plasma - 5 hours after a single administration of trimetazidine 35 mg Cmax in blood plasma is about 115 ng / ml.
Distribution
Binding to plasma proteins - 16%. Easily penetrates through histohematogenous barriers.
Withdrawal
T1 / 2 was 6.5 hours excreted by the kidneys (about 60% - unchanged).
Statement
Coronary heart disease: prevention of angina attacks (in the complex therapy);
chorioretinal circulatory disorders;
Vertigo of vascular origin;
kohleo-vestibular disorders of ischemic nature (tinnitus, hearing loss).
Dosage regimen
Assign to 35 mg (1 tab.) 2 times / day. Tablets are taken orally, during a meal in the morning and evening. Duration of therapy is determined individually.
Side effect
On the part of the digestive system: rarely - stomachalgia, nausea, vomiting.
Allergic reactions: itching.
Other: rarely - headache, feeling of palpitations.
Contraindications
renal failure (CC <15 ml / min);
marked disturbances of liver function;
Pregnancy
Lactation (breastfeeding);
childhood and adolescence to 18 years (efficacy and safety of the drug not established);
Hypersensitivity to the drug's components.
Pregnancy and lactation
The drug is contraindicated during pregnancy and lactation (breastfeeding).
Application for violations of liver function
Contraindications disturbancies liver
Application for violations of renal function
Contraindicated in renal insufficiency (CC <15 ml / min).
Cautions
The product is not intended for relief of angina attacks. In the case of an attack of angina should be correction of treatment.
Effects on ability to drive vehicles and management mechanisms
The product has no effect on the ability to occupations potentially hazardous activities requiring attention and speed of psychomotor reactions.
Overdose
Currently, cases of overdosing Angiozil retard not reported.
Drug Interactions
Drug Interactions drug Angiozil retard not described.
Terms and Conditions of storage
List B. The drug should be stored out of reach of children, dry, dark place at temperatures not above 25 ° C. Shelf life - 2 years.
No comments:
Post a Comment